Earlier maternal tenofovir disoproxil fumarate (TDF) combined with infant vaccination completely eliminated vertical transmission of chronic hepatitis B virus (HBV) from highly viremic mothers, even without the use of hepatitis B immunoglobulin (HBIg), a randomized trial conducted in China found.
At 28 weeks postpartum, mother-to-child transmission was an identical 0% with early maternal TDF therapy starting at 14-16 weeks gestational age (followed by infant HBV vaccination) versus maternal TDF therapy starting at 28 weeks gestational age (followed by infant vaccination plus HBIg), reported Calvin Pan, MD, of the NYU Langone Health in New York City.
At delivery, mothers in the early TDF group had significantly lower HBV-DNA levels (2.37 vs 3.62 log10 IU/mL, P